HealthMore in Health→
Late-Quarter Biotech Dealmaking and Trial Setbacks Show a Sector Still Repricing Risk
Key Takeaways
- The supplied roundup highlights bolt-on deals near the end of Q1 2026.
- It references a Wave decline tied to obesity data.
- It also flags a Sanofi partnership with a T-cell engager startup.
DE
DT Editorial Team··via endpoints.news